title: Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.
abstract: The guideline group was selected to be representative of UK-based medical experts. Ovid MEDLINE, EMBASE and NCBI Pubmed were searched systematically for publications in English from 1980 to 2012 using the MeSH subheading 'lymphoma, CNS', 'lymphoma, central nervous system', 'lymphoma, high grade', 'lymphoma, Burkitt's', 'lymphoma, lymphoblastic' and 'lymphoma, diffuse large B cell' as keywords, as well as all subheadings. The writing group produced the draft guideline, which was subsequently revised by consensus by members of the Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH). The guideline was then reviewed by a sounding board of ~50 UK haematologists, the BCSH and the British Society for Haematology (BSH) Committee and comments incorporated where appropriate. The 'GRADE' system was used to quote levels and grades of evidence, details of which can be found in Appendix I. The objective of this guideline is to provide healthcare professionals with clear guidance on the optimal prevention of secondary central nervous system (CNS) lymphoma. The guidance may not be appropriate to patients of all lymphoma sub-types and in all cases individual patient circumstances may dictate an alternative approach. Acronyms are defined at time of first use.
authors.affiliation: Nottingham University Hospitals NHS Trust, Nottingham, UK.
authors.forename: Andrew
authors.initials: A
authors.lastname: McMillan
authors.forename: Kirit M
authors.initials: KM
authors.lastname: Ardeshna
authors.forename: Kate
authors.initials: K
authors.lastname: Cwynarski
authors.forename: Matthew
authors.initials: M
authors.lastname: Lyttelton
authors.forename: Pam
authors.initials: P
authors.lastname: McKay
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
mesh_terms: D006801:Humans; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000517:prevention & control / Q000556:secondary / Q000628:therapy; D018890:Chemoprevention; D012306:Risk; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents
keywords: central nervous system; chemotherapy; intrathecal; methotrexate; non-Hodgkin lymphoma